Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US based Accumetrics has initiated patient enrollment in Gravitas trial. The trial's primary purpose is to evaluate whether patients that are randomized to a tailored treatment have fewer adverse cardiac events than non-responders randomized to receive standard therapy.
Subscribe to our email newsletter
The Gravitas trial is designed to evaluate the use of the VerifyNow P2Y12 test to identify patients that exhibit a low response to antiplatelet therapy who are at risk for adverse cardiac events, and prove that these at-risk patients will benefit from tailored antiplatelet therapy.
The Gravitas trial is a double-blind, placebo-controlled, randomized trial that employs the VerifyNow P2Y12 test to classify patients undergoing percutaneous coronary intervention receiving a drug-eluting stent as ‘responsive’ or ‘non-responsive’ to clopidogrel.
The study will involve screening approximately 7000 patients at 60-70 investigational centers in the US and Canada, and enrollment is expected to be complete in 2009.
Steven Frankel, CEO of Accumetrics, said: “We believe that the results from Gravitas will provide a more thorough understanding of how patients respond to their antiplatelet therapy, and further substantiate that individualized therapy is more effective than a one-size-fits-all approach.”